Long-term clinical outcomes of COVID-19 patients treated with imatinib

Lancet Respir Med. 2022 Apr;10(4):e34-e35. doi: 10.1016/S2213-2600(22)00052-2. Epub 2022 Feb 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Imatinib Mesylate